deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT01968109

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

Sponsor: Bristol-Myers Squibb

Conditions Neoplasms by Site
Interventions BMS-986213 Nivolumab Relatlimab
Updated 39 times since 2017 Last updated: Dec 16, 2025 Started: Nov 5, 2013 Primary completion: May 22, 2024 Completion: Feb 3, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Neoplasms by Site, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 39 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~Jun 2017 · 3 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~May 2019 · 5 months · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Apr 2020 · 9 months · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Nov 2020 · 2 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Apr 2023 · 13 months · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jul 2023 · 2 months · monthly snapshot~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshot~Oct 2023 – ~Mar 2024 · 5 months · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jun 2024 · 2 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshot~Apr 2025 – ~Sep 2025 · 5 months · monthly snapshot~Sep 2025 – ~Feb 2026 · 5 months · monthly snapshot~Feb 2026 – present · 6 months · monthly snapshot

Change History

39 versions recorded

  1. Feb 2026 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Sep 2025 — Feb 2026 [monthly]

    Completed PHASE1/PHASE2

  3. Apr 2025 — Sep 2025 [monthly]

    Completed PHASE1/PHASE2

    Status: Active Not Recruiting → Completed

  4. Sep 2024 — Apr 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  5. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

▶ Show 34 earlier versions

  1. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  2. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Apr 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Mar 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Oct 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Jul 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. May 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  8. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  9. Mar 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  10. Jan 2022 — Mar 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  11. Dec 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  12. Jan 2021 — Dec 2021 [monthly]

    Recruiting PHASE1_PHASE2

  13. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  14. Sep 2020 — Nov 2020 [monthly]

    Recruiting PHASE1_PHASE2

  15. Jun 2020 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

  16. Apr 2020 — Jun 2020 [monthly]

    Recruiting PHASE1_PHASE2

  17. Jul 2019 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  18. May 2019 — Jul 2019 [monthly]

    Recruiting PHASE1_PHASE2

  19. Dec 2018 — May 2019 [monthly]

    Recruiting PHASE1_PHASE2

  20. Oct 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  21. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

  22. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE1_PHASE2

  23. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE1_PHASE2

  24. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1_PHASE2

  25. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  26. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE1_PHASE2

  27. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE1_PHASE2

  28. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

  29. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE1_PHASE2

  30. Aug 2017 — Oct 2017 [monthly]

    Recruiting PHASE1_PHASE2

  31. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE1_PHASE2

  32. Mar 2017 — Jun 2017 [monthly]

    Recruiting PHASE1_PHASE2

  33. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE1_PHASE2

    Phase: PHASE1 → PHASE1_PHASE2

  34. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
Data source: Bristol-Myers Squibb

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States , Amsterdam, Netherlands , Aurora, United States , Baltimore, United States , Barcelona, Spain , Boston, United States , Brisbane, Australia , Chicago, United States , Chuo-ku, Japan , Copenhagen, Denmark and 42 more locations